{"id":92190,"date":"2025-10-22T08:40:13","date_gmt":"2025-10-22T06:40:13","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=92190"},"modified":"2025-10-22T12:37:06","modified_gmt":"2025-10-22T10:37:06","slug":"ipsen-to-acquire-imcheck-therapeutics-andera-partners","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/","title":{"rendered":"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline"},"content":{"rendered":"<p><span data-contrast=\"auto\">Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. The anticipated acquisition is focused on the lead Phase I\/II program ICT01 in first line acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, and received Orphan Drug Designations from the U.S. Food and Drug Administration and European Medicines Agency in July 2025.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:160,&quot;335559739&quot;:144,&quot;335559740&quot;:240,&quot;335559746&quot;:60}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Many AML patients are unable to tolerate intensive chemotherapy and must rely on lower-intensity options, which often deliver limited and short-lived benefit. This high-risk, unfit population continues to face a significant unmet medical need, highlighting the urgency for new therapies that can improve survival and quality of life.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:160,&quot;335559739&quot;:144,&quot;335559740&quot;:240,&quot;335559746&quot;:60}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u201c<\/span><i><span data-contrast=\"auto\">At completion, the acquisition of ImCheck Therapeutics presents an opportunity for us to expand our pipeline in oncology and reinforces our commitment to deliver transformative therapies to the people who need them most,<\/span><\/i><span data-contrast=\"auto\">\u201d said <\/span><b><span data-contrast=\"auto\">David Loew, CEO, Ipsen<\/span><\/b><span data-contrast=\"auto\">. \u201c<\/span><i><span data-contrast=\"auto\">We feel confident that with the ICT01 promising data combined with Ipsen\u2019s global development and commercialization expertise, we are well positioned to start a Phase IIb\/III trial in 2026.<\/span><\/i><span data-contrast=\"auto\">\u201d\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:160,&quot;335559739&quot;:144,&quot;335559740&quot;:240,&quot;335559746&quot;:60}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Interim data (n=45) orally presented at the annual American Society of Clinical Oncology 2025 from the Phase I\/II EVICTION trial showed treatment with ICT01 in combination with venetoclax and azacitidine (Ven-Aza) achieved very encouraging high responses. In this single-arm trial, treatment response nearly doubled relative to those seen in historical standard of care data across all molecular subtypes in newly diagnosed patients including sub-types typically less responsive to standard of care (Ven-Aza).2 ICT01 in combination with Ven-Aza was also shown to be well tolerated, underscoring ICT01\u2019s potential as a novel immunotherapy to improve outcomes for patients with AML.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span data-contrast=\"auto\">\u201c<\/span><i><span data-contrast=\"auto\">We are thrilled to become part of Ipsen, a company whose ambition for transformative care matches our commitment to bringing innovative treatments to patients. This transaction recognizes groundbreaking science originating from French academia,<\/span><\/i><span data-contrast=\"auto\">\u201d said <\/span><b><span data-contrast=\"auto\">Pierre d\u2019Epenoux, CEO, ImCheck Therapeutics.<\/span><\/b> <i><span data-contrast=\"auto\">\u201cIt also highlights the exceptional work the ImCheck team and our partners have achieved to advance the understanding of butyrophilns and gamma delta T cells. Joining Ipsen will help us accelerate ICT01 toward registrational studies and commercialization. I remain grateful to the patients and investors for their contributions to furthering ImCheck\u2019s pioneering science.\u201d<\/span><\/i><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:160,&quot;335559739&quot;:144,&quot;335559740&quot;:240,&quot;335559746&quot;:60}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"auto\">\u201cWe are pleased to have supported ImCheck Therapeutics since 2022 as Series C co-lead through our BioDiscovery 6 fund. Over the past three years, the company has achieved significant scientific and clinical progress. This transaction reflects France\u2019s scientific excellence, the quality of its entrepreneurs and their financial backing, which continue to position the country as a leading and fast-growing biotech hub in Europe. We warmly congratulate the ImCheck team for their outstanding execution and commitment, and we are confident that Ipsen will further build on this success by advancing ICT01 for the benefit of the patients,\u201d <\/span><\/i><span data-contrast=\"auto\">commented <\/span><b><span data-contrast=\"auto\">Rapha\u00ebl Wisniewski, Partner at Andera Partners.<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:160,&quot;335559739&quot;:144,&quot;335559740&quot;:240,&quot;335559746&quot;:60}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. The anticipated acquisition is focused on the lead Phase I\/II program ICT01 in first&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-92190","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline - ANDERA PARTNERS<\/title>\n<meta name=\"description\" content=\"Ipsen to acquire ImCheck Therapeutics, an Andera Partners portfolio company, expanding its oncology leadership with ICT01, a first-in-class immunotherapy for acute myeloid leukemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Ipsen to acquire ImCheck Therapeutics, an Andera Partners portfolio company, expanding its oncology leadership with ICT01, a first-in-class immunotherapy for acute myeloid leukemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T06:40:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-22T10:37:06+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline\",\"datePublished\":\"2025-10-22T06:40:13+00:00\",\"dateModified\":\"2025-10-22T10:37:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\",\"name\":\"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2025-10-22T06:40:13+00:00\",\"dateModified\":\"2025-10-22T10:37:06+00:00\",\"description\":\"Ipsen to acquire ImCheck Therapeutics, an Andera Partners portfolio company, expanding its oncology leadership with ICT01, a first-in-class immunotherapy for acute myeloid leukemia.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline - ANDERA PARTNERS","description":"Ipsen to acquire ImCheck Therapeutics, an Andera Partners portfolio company, expanding its oncology leadership with ICT01, a first-in-class immunotherapy for acute myeloid leukemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline - ANDERA PARTNERS","og_description":"Ipsen to acquire ImCheck Therapeutics, an Andera Partners portfolio company, expanding its oncology leadership with ICT01, a first-in-class immunotherapy for acute myeloid leukemia.","og_url":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2025-10-22T06:40:13+00:00","article_modified_time":"2025-10-22T10:37:06+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline","datePublished":"2025-10-22T06:40:13+00:00","dateModified":"2025-10-22T10:37:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/"},"wordCount":534,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/","url":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/","name":"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2025-10-22T06:40:13+00:00","dateModified":"2025-10-22T10:37:06+00:00","description":"Ipsen to acquire ImCheck Therapeutics, an Andera Partners portfolio company, expanding its oncology leadership with ICT01, a first-in-class immunotherapy for acute myeloid leukemia.","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/ipsen-to-acquire-imcheck-therapeutics-andera-partners\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ipsen to acquire ImCheck Therapeutics, in Andera Partners\u2019 portfolio, expanding its leadership in oncology, strengthening its pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=92190"}],"version-history":[{"count":2,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92190\/revisions"}],"predecessor-version":[{"id":92196,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92190\/revisions\/92196"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=92190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=92190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}